Literature DB >> 17918268

High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats.

Dominique Thabut1, Khalid A Tazi, Dominique Bonnefont-Rousselot, Maria Aller, Olivier Farges, Marie-Christine Guimont, Zera Tellier, Cecile Guichard, Eric Ogier-Denis, Thierry Poynard, Richard Moreau, Didier Lebrec.   

Abstract

UNLABELLED: In patients with cirrhosis, endotoxic shock is a major complication of portal hypertension, which is related partly to intrahepatic endothelial nitric oxide synthase (eNOS) down-regulation. High-density lipoproteins (HDLs), whose plasma levels are reduced in cirrhosis, have an anti-inflammatory effect by neutralizing circulating lipopolysaccharide (LPS), and they increase eNOS activity in endothelial cells. Therefore, the aim of this study was to assess the effects of reconstituted high-density lipoprotein (rHDL) administration on the LPS-induced proinflammatory response, intrahepatic eNOS regulation, and portal hypertension in cirrhotic rats. Cirrhotic and control rats were pretreated with rHDL or saline and challenged with LPS or saline. The neutralization of LPS in HDL was assessed by the measurement of HDL-bound fluorescent LPS levels. Plasma tumor necrosis factor alpha (TNFalpha) and lipopolysaccharide binding protein (LBP) levels were measured. The expression of hepatic TNFalpha, LBP, inducible nitric oxide synthase (iNOS), and caveolin-1 (a major eNOS inhibitor) and the activity of protein kinase B (Akt; a major eNOS activator) and eNOS were determined. The portal pressure was measured. The plasma HDL levels were significantly lower in cirrhotic rats than in control rats. In cirrhotic rats, the plasma levels of HDL-bound fluorescent LPS were 50% lower than those in controls, and they were restored after rHDL administration. The plasma TNFalpha levels were significantly higher in LPS-challenged cirrhotic rats than in controls and significantly decreased after rHDL administration. rHDL administration decreased hepatic TNFalpha, LBP, iNOS, and caveolin-1 expression, restored hepatic eNOS and Akt activity, and significantly lowered the portal pressure and intrahepatic vascular resistance.
CONCLUSION: In cirrhotic rats, rHDL administration decreases the hepatic proinflammatory signals induced by LPS, restores the hepatic eNOS activity, and lowers the portal pressure. This suggests that the decrease in circulating HDL in cirrhosis plays a role in the excessive proinflammatory response and intrahepatic eNOS down-regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918268     DOI: 10.1002/hep.21875

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

4.  A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection.

Authors:  Aimee C Hodowanec; Rebecca D Lee; Kirsten E Brady; Weihua Gao; Stacey Kincaid; Jill Plants; Mieoak Bahk; Nigel Mackman; Alan L Landay; Gregory D Huhn
Journal:  BMC Infect Dis       Date:  2015-04-17       Impact factor: 3.090

Review 5.  Hepatic fibrosis.

Authors:  Jingjing Jiao; Scott L Friedman; Costica Aloman
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

6.  The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection.

Authors:  Ashraf Mohamadkhani; Kourosh Sayemiri; Reza Ghanbari; Elham Elahi; Hossein Poustchi; Ghodratollah Montazeri
Journal:  Virol J       Date:  2010-09-14       Impact factor: 4.099

Review 7.  Gut microbiota and diabetes: from pathogenesis to therapeutic perspective.

Authors:  Rémy Burcelin; Matteo Serino; Chantal Chabo; Vincent Blasco-Baque; Jacques Amar
Journal:  Acta Diabetol       Date:  2011-10-02       Impact factor: 4.280

8.  Interaction between periodontitis and liver diseases.

Authors:  Pengyu Han; Dianxing Sun; Jie Yang
Journal:  Biomed Rep       Date:  2016-07-18

9.  Experimental obstructive cholestasis: the wound-like inflammatory liver response.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jose García-Domínguez; Jose-Ignacio Arias; Manuel Durán; Jaime Arias
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03

Review 10.  Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.

Authors:  Jaap Mulder; Saul J Karpen; Uwe J F Tietge; Folkert Kuipers
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.